Medication use in breast cancer survivors compared to midlife women
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Many breast cancer survivors (BCS) take multiple medications for health problems associated with the treated cancer and other noncancer comorbidities. However, there is no published, large-scale descriptive evaluation of medication use in BCS compared to midlife women. The purpose of this study was (1) to compare the number and types of prescription medications and over-the-counter medications between BCS and midlife women without cancer and (2) to assess possible drug–drug interactions by evaluating the cytochrome P450 isoform properties of medications (inductors and inhibitors) in both groups.
A cross-sectional, descriptive, comparative design was used. Baseline data from 98 BCS and 138 midlife women without cancer was analyzed from a behavioral intervention trial for menopausal symptoms.
BCS were taking significantly more prescription medications and a larger variety of different types of medication classifications (p < 0.05) after controlling for group differences (race, noncancer comorbid conditions, marital status, income, and smoking) in demographics. Twenty-four women were taking at least one medication considered to be a cytochrome P450 isoforms (CYP) inhibitor or inducer capable of clinical drug–drug interactions with no differences in CYP inhibitors or inducers found between groups.
BCS are taking a vast array of medications during survivorship. It is unclear if prescription medications are managed by a single healthcare provider or several providers. Clinical implications are to monitor for possible interactions among the various prescription medications, over-the-counter medications, and supplements. Implications for behavioral and biomedical research are that clinical studies need to carefully assess and account for multiple medication uses.
Relevance of the study
The findings of this study are relevant to research and practice for both oncology and general practitioners. The importance of assessing medication information provides information about symptom management in individuals surviving cancer. In addition, the potential interaction of drugs impacts efficacy of various treatments and impacts compliance by patients.
- Otte JL, Carpenter JS, Russell KM, Bigatti S, Champion VL (2010) Prevalence, severity, and correlates of sleep–wake disturbances in long-term breast cancer survivors. J Pain Symptom Manage 39(3):535–547 CrossRef
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90 CrossRef
- Altman RB, Flockhart DA, Sherry ST, Oliver DE, Rubin DL, Klein TE (2003) Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 13(1):3–5 CrossRef
- Flockhart DA, Rae JM (2003) Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J 3(1):3–5 CrossRef
- Stearns V, Davidson NE, Flockhart DA (2004) Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 4(3):143–153 CrossRef
- Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478 CrossRef
- Moore TA, Berger AM, Dizona P (2011) Sleep aid use during and following breast cancer adjuvant chemotherapy. Psychooncology 20(3):321–325 CrossRef
- Costantini C, Ale-Ali A, Helsten T (2011) Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med 14(5):563–566 CrossRef
- Miller P, Demark-Wahnefried W, Snyder DC, Sloane R, Morey MC, Cohen H, Kranz S, Mitchell DC, Hartman TJ (2008) Dietary supplement use among elderly, long-term cancer survivors. J Cancer Surviv 2(3):138–148 CrossRef
- Velentzis LS, Keshtgar MR, Woodside JV, Leathem AJ, Titcomb A, Perkins KA, Mazurowska M, Anderson V, Wardell K, Cantwell MM (2011) Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study. Breast Cancer Res Treat 128(2):473–482 CrossRef
- Ridner SH, Dietrich MS (2008) Self-reported comorbid conditions and medication usage in breast cancer survivors with and without lymphedema. Oncol Nurs Forum 35(1):57–63 CrossRef
- Carpenter JS, Wu J, Burns DS, Yu M (2012) Perceived control and hot flashes in treatment-seeking breast cancer survivors and menopausal women. Cancer Nurs 35(3):195–202 CrossRef
- Staff PDR (2011) PDR consumer guide to prescription drugs. PDR Consumer, New York, p 1828, 1 online resource
- Drug Interactions: cytochrome P450 drug interaction table. http://medicine.iupui.edu/clinpharm/ddis/table.aspx.
- Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol: Off J Am Soc Cli Oncol 26(4):665–673 CrossRef
- Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol: Off J Am Soc Cli Oncol 30(9):936–942 CrossRef
- North American Menopause Society N (2010) Menopause practice: a clinician’s guide, 4th edn. North American Menopause Society, Mayfield Heights
- Marchigiano G (1999) Calcium intake in midlife women: one step in preventing osteoporosis. Orthop Nurs/Natl Assoc Orthop Nurses 18(5):11–18, quiz 19–20
- Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, Davis RL, Skaar T, Lamba J, Savova G (2011) The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther 89(3):379–386 CrossRef
- Medication use in breast cancer survivors compared to midlife women
Supportive Care in Cancer
Volume 21, Issue 7 , pp 1827-1833
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Breast cancer survivor
- Medication use
- Drug interaction
- Industry Sectors
- Author Affiliations
- 1. Indiana University School of Nursing, 1111 Middle Drive NU W401, Indianapolis, IN, 46202, USA
- 2. Division of Clinical Pharmacology, Indiana University, Indianapolis, IN, USA
- 3. Department of Biostatistics, Indiana University, Indianapolis, IN, USA
- 4. Division of Biostatistics, University of Wisconsin, Madison, WI, USA
- 5. Department of Music and Arts Technology, Purdue School of Engineering and Technology, IUPUI, Indianapolis, IN, USA